NCT06732505招募中1 期
A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With Inoperable, Locally Advanced or Metastatic, Progressive, Well-Differentiated,SSTR+ GEP-Nens
Peking University Cancer Hospital & Institute1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2024年9月29日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Safety and tolerability of 225Ac-DOTATATE
研究概览
简要总结
This is a phase I study to assess the safety and efficacy of [225Ac]Ac-DOTATATE in patients with inoperable, locally advanced or metastatic, progressive, Well-Differentiatedwell differentiated, somatostatin receptor positive gastroenteropancreatic neuroendocrine neoplasms with either no prior history of peptide receptor radionuclide therapy (PRRT naive) or prior history of peptide receptor radionuclide therapy (Previous PRRT).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have the ability to understand and sign an approved informed consent form (ICF).
- •Patients must be >= 18 and <＝80 years of age.
- •Histopathologically confirmed G1 or G2 or G3 GEP-NET or GEP-NEC；
- •Unresectable locally advanced or metastatic GEP-NET which confirmed by imaging examination.
- •G1 or G2 NET patients: previously received fixed-dose Octreotide LAR (20-30 mg/3-4 weeks) for at least 12 weeks of continuous treatment with disease progression;G3 NET orNEC patients: previously received at least 1 line therapy with disease progression.
- •Presence of at least 1 measurable site of disease (based on RECIST 1.1).
- •SSTR-PET positive.
- •ECOG score of 0 or
- •Life expectancy of at least 12 weeks.
- •Sufficient bone marrow capacity and organ function:
- •Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 ml/min (Cockcroft Gault formula).
- •Hemoglobin≥90g/L, neutrophil count ≥1.5×10^9/L, platelets≥100×10^9/L. Serum total bilirubin ≤1.5×ULN. Serum albumin ≥30g/L. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5×ULN，or ALT/AST≤5×ULN with liver metastases.
- •Partially activated prothrombin time (APTT) ≤1.5 x ULN.
- •Subjects of childbearing potential voluntarily use an effective method of contraception, such as condoms, oral or injectable contraceptives, IUDs, etc., during treatment and within 6 months of the last use of the trial drug.
排除标准
- •Pregnant or lactating females.
- •Received the following treatments within 4 weeks prior to initiation of study treatment, including but not limited to surgery (except biopsy), radical radiotherapy, hepatic artery interventional embolization, cryoablation of liver metastases, or radiofrequency ablation.
- •Received systemic antitumor therapy such as targeted therapy, immunotherapy, antitumor herbal therapy, chemotherapy within 4 weeks prior to initiation of study treatment.
- •Rapid progression with previous PRRT therapy.
- •Any patient receiving treatment with short-acting Octreotide, which cannot be interrupted for 24 h before and 24 h after the administration of initiation of study treatment, or any patient receiving treatment with Octreotide LAR, which cannot be interrupted for at least 6 weeks before the administration of initiation of study treatment.
- •Toxicity of prior antitumor therapy has not returned to ≤ grade 1 levels (except for alopecia).
- •Received external beam radiation therapy for bone metastases within 2 weeks prior to initiation of study treatment.
- •Known brain metastases, unless these metastases have been treated and stabilized for at least 24 weeks, prior to enrollment in the study.
- •Uncontrolled congestive heart failure.
- •uncontrolled diabetes mellitus, including baseline fasting glucose > 2 x ULN.
- •Known other malignancies (except for those without recurrence within 5 years after adequate treatment).
- •Known hypersensitivity to Lutetium[177Lu] Oxodotreotide Injection or [225Ac]Ac-DOTATATE Injection and their excipients.
- •Known to be unsuitable for enhanced CT or MRI contrast imaging due to allergic reaction or renal insufficiency.
- •Any clinically significant active infection.
- •Participated in other drug clinical trials within 4 weeks prior to initiation of study treatment and received treatment with the corresponding trial drug.
- •Any other disease, mental status or surgical condition that is uncontrolled, may interfere with study completion (including poor compliance) or is inappropriate for the use of the investigational drug.
- •Other treatment options (e.g., chemotherapy, targeted therapy) that, in the opinion of the investigator, are more appropriate for the patient than the treatment provided in the study based on the patient's disease characteristics.
- •Unsuitable for the study for any reason, in the opinion of the investigator.
研究组 & 干预措施
[225Ac]Ac-DOTATATE
Experimental
Investigational radiotherapeutic drug targeting somatostatin receptor-positive neuroendocrine neoplasms in PRRT naive patients (Cohort 1) and previous PRRT patients (Cohort 2)
干预措施: [225Ac]Ac-DOTATATE (Drug)
结局指标
主要结局
Safety and tolerability of 225Ac-DOTATATE
时间窗: 32 weeks following first 225Ac-DOTATATE injection
Incidence and severity of adverse events (AEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
Recommended phase II dose of 225Ac-DOTATATE
时间窗: First 56 days following first 225Ac-DOTATATE injection
Rate incidence of dose-limiting toxicities (DLT)
次要结局
- ORR(24 months after last dose administration)
- PFS(24 months after last dose administration)
- DoR(24 months after last dose administration)
- TTP(24 months after last dose administration)
- DCR(24 months after last dose administration)
- 12-month PFS Rate(From date of enrollment until date of progression or date of death from any cause, whichever comes first，assessed up to approximately 24 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic CancersAdvanced CancerMetastatic CancerNCT05204147City of Hope Medical Center20
招募中
1 期
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic SyndromeAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT06287944City of Hope Medical Center15
Unknown
1 期
GR1405 Injection in Patients With Advanced Solid Tumor or LymphomaTumor, SolidLymphomaNCT03731390Chinese Academy of Medical Sciences30
进行中（未招募）
1 期
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabExtensive Stage Small Cell Lung CancerNCT05142696Novartis Pharmaceuticals55
招募中
1 期
BC008-1A Injection for Recurrent CNS WHO G4 GliomaGlioma Tumor RecurrenceGlioma, Recurrent High GradeGlioblastomas (GBM)Glioblastoma WHO Grade IVGliomaNCT06773481Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.40